EXONATE PQ-110-001

EXONATE PQ-110-001

Phase 1b/2 – A Randomised, Single-Blind, Placebo Controlled, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of EXN407 in subjects with Centre Involved Diabetic Macular Oedema secondary to Diabetes Mellitus.

ClinicalTrials.gov identifier: NCT04565756

Principal Investigator – Dr Fred Chen

For more information please contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment